BPC -157 10mg 10mg/10ml 1 Vial by Swiss Pharma

Usage

1. Calculate your dose volume: At 1 mg/ml (10 mg/10 ml), a 250 µg dose equals 0.25 ml — draw to the 25-unit mark on a 100-unit insulin syringe.
2. Reconstitute correctly: Inject bacteriostatic water slowly down the inner glass wall of the vial; do not shake — tilt and rotate gently to dissolve the lyophilised powder fully.
3. Time your first injection: Administer the morning dose on an empty stomach or at least 30 minutes after a GH secretagogue to allow receptor-sensitisation overlap during the GH pulse.
4. Select and rotate injection sites: Use the lower abdomen or outer thigh for subcutaneous delivery; rotate sites daily to prevent localised inflammation during a 10–12 week fat-loss block.
5. Pair with your dietary protocol: BPC-157's vascular support effects are most relevant during caloric deficits — ensure adequate protein intake (≥ 1.8 g/kg bodyweight) to preserve lean mass while lipolysis is active.
6. Store responsibly: Keep the reconstituted vial at 2–8 °C, away from light; log the reconstitution date and discard any remaining solution after 28 days to maintain peptide stability and sterility.

Warnings

Frequently asked questions

How does BPC-157 support growth hormone-driven fat loss?

BPC-157 upregulates GH receptor expression in peripheral tissues, increasing sensitivity to both endogenous and exogenous growth hormone. This receptor-level amplification enhances the lipolytic signal that GH delivers to adipocytes, resulting in greater free fatty acid mobilisation per unit of GH present — making BPC-157 a mechanistically distinct adjunct in GH-assisted cutting protocols.

What daily dose of BPC-157 is used alongside a GH-based lipolysis stack?

Research-informed protocols typically use 250–500 µg of BPC-157 per day, divided into two subcutaneous injections of 125–250 µg each. This range corresponds to the 10 µg/kg dosing observed in rodent vascular and receptor-upregulation studies. At Swiss Pharma's 1 mg/ml concentration, a 250 µg dose requires only 250 µl drawn with a standard insulin syringe.

When do measurable fat-loss benefits from a BPC-157 and GH combination become apparent?

GH receptor sensitisation is generally considered a gradual process; most structured protocols run 8–12 weeks before subjective and objective changes in body composition are assessed. BPC-157's vascular support effects — enhanced tissue perfusion via NOS pathway activation — may be noticeable earlier, within 2–4 weeks, as improved recovery during a caloric deficit.

How do you reconstitute and store a Swiss Pharma BPC-157 10mg vial?

Add 10 ml of bacteriostatic water slowly down the side of the vial to yield a 1 mg/ml solution; avoid vigorous shaking to prevent peptide degradation. Store the reconstituted vial refrigerated at 2–8 °C and use within 28 days of reconstitution. Before first use, allow the vial to reach room temperature to minimise injection discomfort.

Can BPC-157 be used with an insulin syringe, and what needle gauge is appropriate?

Yes — BPC-157 at 1 mg/ml is fully compatible with standard 29–31 gauge, 0.5 ml insulin syringes, which are preferred for subcutaneous administration. The fine gauge minimises injection-site discomfort and allows accurate volume measurement at the small doses (100–250 µl) typical in lipolysis protocols. Rotate injection sites — abdomen, outer thigh — to prevent localised irritation. (2) angle_used

Manufacturer

Swiss Pharma's BPC-157 10 mg/10 ml vial occupies a defined position within the company's injectable peptide portfolio — a product line that spans GLP-1 receptor agonists, metabolic peptides, and research-grade cytoprotective compounds, all manufactured under the same quality framework. What distinguishes the portfolio approach is the extension of identical batch-release standards across every peptide class regardless of mechanism: each vial, irrespective of active ingredient, is released only after two independent, lot-specific laboratory verifications are on file. For this BPC-157 line specifically, those verifications are reversed-phase HPLC confirmation that active peptide content meets the declared 1 mg/ml specification, and LAL (Limulus Amebocyte Lysate) endotoxin testing confirming that the sterile solution satisfies injectable-grade bacterial endotoxin thresholds. Swiss Pharma's decision to apply this dual-verification architecture uniformly across its peptide range — rather than reserving it for higher-volume SKUs — reflects a portfolio-level commitment to injectable safety standards.